NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free AURA Stock Alerts $7.70 +0.07 (+0.92%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$7.60▼$8.0750-Day Range$7.09▼$9.2452-Week Range$5.99▼$13.50Volume140,008 shsAverage Volume182,807 shsMarket Capitalization$294.60 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aura Biosciences alerts: Email Address Aura Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside172.7% Upside$21.00 Price TargetShort InterestBearish7.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 6 Articles This WeekInsider TradingSelling Shares$171,610 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.80) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector706th out of 939 stocksBiological Products, Except Diagnostic Industry117th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Aura Biosciences has a forecasted upside of 172.7% from its current price of $7.70.Amount of Analyst CoverageAura Biosciences has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.27% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently increased by 4.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AURA. Previous Next 3.1 News and Social Media Coverage News SentimentAura Biosciences has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aura Biosciences this week, compared to 1 article on an average week.Search Interest4 people have searched for AURA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $171,610.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aura Biosciences are expected to decrease in the coming year, from ($1.80) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Aura Biosciences Stock (NASDAQ:AURA)Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Read More AURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AURA Stock News HeadlinesMarch 27, 2024 | investorplace.comAURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023March 27, 2024 | benzinga.comRecap: Aura Biosciences Q4 EarningsMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 27, 2024 | businesswire.comAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 23, 2024 | americanbankingnews.comCritical Review: Caribou Biosciences (NASDAQ:CRBU) & Aura Biosciences (NASDAQ:AURA)March 13, 2024 | msn.comNational Assembly Counters Doctors Petition on SHIFFebruary 26, 2024 | businesswire.comAura Biosciences to Participate in Upcoming Investor ConferencesFebruary 23, 2024 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Short Interest ReportMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.January 7, 2024 | finance.yahoo.comOwning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),January 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)December 11, 2023 | finance.yahoo.comWall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a BetDecember 9, 2023 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Analyst Ratings, Price Targets, PredictionsDecember 7, 2023 | finance.yahoo.comAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNovember 23, 2023 | finance.yahoo.comWall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to TradeNovember 13, 2023 | markets.businessinsider.comCorrection: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common StockNovember 12, 2023 | finance.yahoo.comDavid Johnson Bought 232% More Shares In Aura BiosciencesNovember 11, 2023 | msn.comInsider Trading: Aura Biosciences Stock (NASDAQ:AURA) Bought by Insiders to the Tune of $16MNovember 10, 2023 | msn.comAura Biosciences director David Johnson buys common shares worth ~$1.44MNovember 10, 2023 | markets.businessinsider.comPortfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common StockNovember 8, 2023 | markets.businessinsider.comPromising Phase 2 Trial Results and Market Potential Bolster Aura Biosciences’ Buy RatingNovember 7, 2023 | msn.comWhy Aura Biosciences Stock Hit A New 52-Week Low TodayNovember 7, 2023 | markets.businessinsider.comAura Biosciences Prices Public Offering Of 11 Mln Shares Of At $9.00/shrNovember 6, 2023 | marketwatch.comAura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-SarNovember 6, 2023 | finance.yahoo.comAura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal MelanomaNovember 5, 2023 | morningstar.comAura Biosciences Inc AURANovember 1, 2023 | businesswire.comAura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with ...See More Headlines Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AURA CUSIPN/A CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$23.00 Low Stock Price Target$19.00 Potential Upside/Downside+172.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.83% Return on Assets-35.31% Debt Debt-to-Equity RatioN/A Current Ratio14.13 Quick Ratio14.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.67 per share Price / Book1.15Miscellaneous Outstanding Shares38,260,000Free Float36,003,000Market Cap$294.60 million OptionableNot Optionable Beta0.40 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Elisabet de los Pinos Ph.D. (Age 51)Founder, CEO, President & Director Comp: $795.3kMs. Julie B. Feder (Age 54)CFO, Secretary & Treasurer Comp: $505.45kDr. Mark Plavsic D.V.M. (Age 63)Ph.D., Chief Technology Officer Mr. Patrick NealonSenior Vice President of Clinical Development OperationsDr. Bruce Brown M.D.Senior VP & Therapeutic Area Head of Urologic OncologyDr. Anthony Daniels M.D.Therapeutic Area Head of Ocular OncologyDr. Richard Mountfield Ph.D.Senior Vice President of Regulatory Affairs & QualityDr. Jill Hopkins M.D.Chief Medical Officer & President of Research and DevelopmentMore ExecutivesKey CompetitorsAdverum BiotechnologiesNASDAQ:ADVMFennec PharmaceuticalsNASDAQ:FENCPoseida TherapeuticsNASDAQ:PSTXBlack Diamond TherapeuticsNASDAQ:BDTXSOPHiA GENETICSNASDAQ:SOPHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 699,337 shares on 3/11/2024Ownership: 4.523%Goldman Sachs Group Inc.Bought 44,097 shares on 3/1/2024Ownership: 2.711%Eventide Asset Management LLCBought 2,777,777 shares on 2/20/2024Ownership: 15.166%Price T Rowe Associates Inc. MDBought 2,663 shares on 2/16/2024Ownership: 1.724%Citadel Advisors LLCBought 1,100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AURA Stock Analysis - Frequently Asked Questions Should I buy or sell Aura Biosciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AURA shares. View AURA analyst ratings or view top-rated stocks. What is Aura Biosciences' stock price target for 2024? 3 analysts have issued 12-month target prices for Aura Biosciences' shares. Their AURA share price targets range from $19.00 to $23.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price. View analysts price targets for AURA or view top-rated stocks among Wall Street analysts. How have AURA shares performed in 2024? Aura Biosciences' stock was trading at $8.86 at the beginning of the year. Since then, AURA stock has decreased by 13.1% and is now trading at $7.70. View the best growth stocks for 2024 here. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) released its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.06. What ETFs hold Aura Biosciences' stock? ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include AltShares Event-Driven ET (EVNT).Range Cancer Therapeutics ETF (CNCR). When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Aura Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Matrix Capital Management Company LP (18.09%), Eventide Asset Management LLC (15.17%), Vanguard Group Inc. (4.52%), Vanguard Group Inc. (4.52%), Nantahala Capital Management LLC (3.45%) and Goldman Sachs Group Inc. (2.71%). Insiders that own company stock include Cadmus Rich, David Michael Johnson, Julie B Feder, Los Pinos Elisabet De, Matrix Capital Management Comp and Rosch Mark De. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AURA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.